14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MRNA vs GMAB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Genmab A/S ADS (GMAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas GMAB carries 40.1/100 (SELL) at $50.60 (29.3x Forward P/E, 30.6% operating margin).
Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both MRNA (40.3/100 SELL) and GMAB (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs GMAB. Trailing 12-month operating profitability (MRNA -80.8% vs GMAB 30.6%) and valuation multiples (MRNA 23.0x vs GMAB 29.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment38.8% of Rev ($980M)
90D Engineering Disclosures0 Published · mRNA Therapeutics
GMAB Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $31.7B market capitalization and 30.6% operating margin.
OpEx & R&D Reinvestment62.1% of Rev ($2.67B)
90D Engineering Disclosures0 Published
Investor FAQ MRNA vs GMAB Key Questions & Quantitative Answers
As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Genmab A/S ADS (GMAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas GMAB carries 40.1/100 (SELL) at $50.60 (29.3x Forward P/E, 30.6% operating margin). Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both MRNA (40.3/100 SELL) and GMAB (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with GMAB at +16.1% YoY revenue growth and -14.7% YoY earnings growth on $4.30B TTM revenue (92.7% gross margin, 30.6% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus $4.30B for GMAB. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 62.1% of Rev ($2.67B) (0 disclosures) for GMAB.
MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas GMAB trades at 29.3x Forward P/E, 43.9x Trailing P/E, 4.61x PEG, and 7.4x EV/Revenue (31.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus GMAB (12.1% ROE) capital efficiency.
In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, GMAB carries 32.4% implied volatility (9th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 106% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.